-
US Supreme Court maintains mail access to abortion pill for now
-
Hantavirus ship heads to Netherlands after passengers flown home
-
Trump warns Mideast truce on 'life support', Iran says ready for any aggression
-
Frustrated Trump learns he doesn't have the cards on Iran
-
Cannes Film Festival defends male-dominated competition
-
Patel, Miller lead Delhi to record-breaking win over Punjab
-
Final hantavirus ship evacuations begin after weather delay
-
No longer peripheral: SKorean director makes Cannes history
-
Military strikes, gang massacres in Nigeria kill around 100 civilians
-
SNC Scandic Coin: Real assets meet digital utility
-
SNC Scandic Coin: реальные активы и цифровые возможности
-
Venezuela has 'never considered' becoming 51st US state: acting president
-
Wembanyama escapes playoff suspension after ejection: NBA source
-
Trump to suspend US gas tax as Iran war spikes prices
-
Macron announces 23 bn euros of investment at Africa summit
-
Oil rises, stocks mostly higher on US-Iran deadlock
-
SNC Scandic Coin: поєднання реальних активів та цифрової функціональності
-
Sinner demolishes Popyrin to stroll into Italian Open last 16
-
Dua Lipa sues Samsung in US over use of her likeness on TV box
-
White House press gala shooting suspect pleads not guilty
-
England women's great Mead to leave Arsenal at the end of the season
-
NATO 'could never be more important than today': Canada FM
-
Boycotters Spain, Ireland, Slovenia will not show Eurovision
-
Oil rises, stocks mixed on US-Iran deadlock
-
Tens of millions risk hunger as Hormuz standoff blocks fertiliser, UN official says
-
Beatles to open first London museum on site of last gig
-
Lewis-Skelly says leaders Arsenal know 'job is not yet done'
-
Boycotting Spain, Ireland, Slovenia will not show Eurovision
-
Every goalie 'illegally blocked' says West Ham's Hermansen after Arsenal agony
-
Thai police arrest 9 in largest ivory seizure in decade
-
Hantavirus: confirmed cases by nationality
-
US, French evacuees from hantavirus ship test positive
-
China seeks 'more stability' as it confirms Trump-Xi meet
-
Man City boss Guardiola backs Marmoush to play big role in run-in
-
Philippine lawmakers vote to impeach VP Sara Duterte
-
No end to deadlock as Iran, US reject talks terms
-
Iran hangs 'elite student' on espionage charges: NGOs
-
Party's over: China tells fans to end birthday blowouts for sport idols
-
Australia to quarantine six people from hantavirus ship
-
Groundbreaking: 'Controlled' quakes triggered under Swiss Alps
-
Nazi-looted portrait found in home of Dutch SS leader's family: art sleuth
-
US citizen from hantavirus ship tests positive
-
Hantavirus outbreak renews painful memories for Patagonian village
-
Myanmar complains over pariah treatment in ASEAN bloc
-
Domestic dominance not enough, Barca's ambition is European glory
-
Oil soars as Trump rejects Iran's terms
-
Spurs star Wembanyama ejected for elbowing Wolves' Reid
-
In India, heat-triggered insurance offers 'some relief'
-
Under-threat UK PM Starmer to attempt reset after disastrous polls
-
The first 48-team World Cup -- more opportunities, less jeopardy?
Study shows how fast kilos return after ending weight-loss drugs
When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.
But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.
A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.
They have been found to help people lose between 15-20 percent of their body weight.
"This all appears to be a good news story," said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.
However, recent data has suggested that "around half of people discontinue these medications within a year," she told a press conference.
This might be because of common side effects such as nausea or the price -- these drugs can cost over $1,000 a month in the US.
So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.
Six of the clinical trials involved semaglutide -- the ingredient used in Novo Nordisk's brands Ozempic and Wegovy -- and tirzepatide used for Eli Lilly's Mounjaro and Zepbound.
While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.
However after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.
The researchers projected that the participants would return to their original weight in 18 months.
Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.
People who were instead put on programmes that included diet and exercise -- but not drugs -- lost significantly less weight. However it took an average of four years for them to regain their lost kilos.
This meant that people taking the drugs regained their weight four times faster.
- 'Starting point, not a cure' -
"Greater weight loss tends to result in faster weight regain," lead study author Sam West of Oxford University explained.
But separate analysis showed that weight gain was "consistently faster after medication, regardless of the amount of weight lost in the first place," he added.
This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.
Jebb emphasised that GLP-1 drugs "are a really valuable tool in obesity treatment -- but obesity is a chronic relapsing condition."
"One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication," Jebb said.
If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.
"This new data makes it clear they are a starting point, not a cure," said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.
"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.
L.Henrique--PC